Roger Sheng-Chieh Lo, M.D., Ph.D.
Work Email Address:
rlo@mednet.ucla.edu
Work Phone Number:
(310)825-5420
https://www.uclahealth.org/roger-lo
http://gradprogram-faculty.pharmacology.ucla.edu/institution/personnel?personnel_id=232427
Mailing Address:
STE 450, 200 Medical Plaza
Los Angeles, CA 90095
Affiliations
Biography
Dr. Roger Lo is Professor of Medicine/Dermatology, Associate Chief of Dermatology and Director of the Dermatology STAR Program at UCLA’s David Geffen School of Medicine. He earned his BS in Biology with Honors and Distinction in 1994 from Stanford University and his MD and PhD degrees from the Tri-institutional (Weill Cornell, Memorial Sloan-Kettering, and Rockefeller) MD-PhD Program in 2002. After completing residency and postdoctoral work at UCLA, he joined the faculty in 2008. Work from his group has been recognized for providing the major scientific rationale toward the use of inhibitors of BRAF and MEK in combination to effectively treat melanoma – a therapeutic approach that is now globally considered the standard of care. Studies from his group have provided rationale to additional clinical trials and foundational knowledge on the roles of tumor heterogeneity, non-genomic processes and the tumor microenvironment in determining clinical responses to mutation-targeted and immunotherapies. His work has been published in Nature, New England Journal of Medicine, Cancer Discovery, Cancer Cell, and Cell. Dr. Lo was elected to the American Society for Clinical Investigation in 2012 and American Dermatological Association in 2015. In 2013 Dr. Lo received the 33rd Annual Award for Outstanding Achievement in Cancer Research from the American Association for Cancer Research (AACR). In 2017, Dr. Lo received the inaugural AACR-Waun Ki Hong Award for Outstanding Achievement in Cancer Research. Dr. Lo has received the Innovative Research Grant from Stand Up to Cancer and the Milstein Innovation Award for the American Skin Association. He currently serves on the Editorial Board of Cancer Discovery.
Publications
|
Huang Lu, Malu Shruti, McKenzie Jodi A, Andrews Miles C, Talukder Amjad H, Tieu Trang, Karpinets Tatiana, Haymaker Cara, Forget Marie-Andrée, Williams Leila J, Wang Zhe, Mbofung Rina M, Wang Zhi-Qiang, Davis Richard Eric, Lo Roger S, Wargo Jennifer A, Davies Michael A, Bernatchez Chantale, Heffernan Timothy, Amaria Rodabe N, Korkut Anil, Peng Weiyi, Roszik Jason, Lizée Gregory, Woodman Scott E, Hwu Patrick The RNA-binding Protein MEX3B Mediates Resistance to Cancer
Immunotherapy by Downregulating HLA-A Expression.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2018; 24(14):
3366-3376.
Huang Dian, Leslie Kevin A, Guest Daniel, Yeshcheulova Olga, Roy Irena J, Piva Marco, Moriceau Gatien, Zangle Thomas A, Lo Roger S, Teitell Michael A, Reed Jason High-Speed Live-Cell Interferometry: A New Method for Quantifying
Tumor Drug Resistance and Heterogeneity.
Analytical chemistry.
2018; 90(5):
3299-3306.
Hong Aayoung, Moriceau Gatien, Sun Lu, Lomeli Shirley, Piva Marco, Damoiseaux Robert, Holmen Sheri L, Sharpless Norman E, Hugo Willy, Lo Roger S Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant
Melanoma.
Cancer discovery.
2018; 8(1):
74-93.
Song Chunying, Piva Marco, Sun Lu, Hong Aayoung, Moriceau Gatien, Kong Xiangju, Zhang Hong, Lomeli Shirley, Qian Jin, Yu Clarissa C, Damoiseaux Robert, Kelley Mark C, Dahlman Kimberley B, Scumpia Philip O, Sosman Jeffrey A, Johnson Douglas B, Ribas Antoni, Hugo Willy, Lo Roger S Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during
MAPKi-Induced Melanoma Regression and Early Adaptation.
Cancer discovery.
2017; 7(11):
1248-1265.
Shin Daniel Sanghoon, Zaretsky Jesse M, Escuin-Ordinas Helena, Garcia-Diaz Angel, Hu-Lieskovan Siwen, Kalbasi Anusha, Grasso Catherine S, Hugo Willy, Sandoval Salemiz, Torrejon Davis Y, Palaskas Nicolaos, Rodriguez Gabriel Abril, Parisi Giulia, Azhdam Ariel, Chmielowski Bartosz, Cherry Grace, Seja Elizabeth, Berent-Maoz Beata, Shintaku I Peter, Le Dung T, Pardoll Drew M, Diaz Luis A, Tumeh Paul C, Graeber Thomas G, Lo Roger S, Comin-Anduix Begoña, Ribas Antoni Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
Cancer discovery.
2017; 7(2):
188-201.
Hugo Willy, Zaretsky Jesse M, Sun Lu, Song Chunying, Moreno Blanca Homet, Hu-Lieskovan Siwen, Berent-Maoz Beata, Pang Jia, Chmielowski Bartosz, Cherry Grace, Seja Elizabeth, Lomeli Shirley, Kong Xiangju, Kelley Mark C, Sosman Jeffrey A, Johnson Douglas B, Ribas Antoni, Lo Roger S Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy
in Metastatic Melanoma.
Cell.
2017; 168(3):
542.
Zaretsky Jesse M, Garcia-Diaz Angel, Shin Daniel S, Escuin-Ordinas Helena, Hugo Willy, Hu-Lieskovan Siwen, Torrejon Davis Y, Abril-Rodriguez Gabriel, Sandoval Salemiz, Barthly Lucas, Saco Justin, Homet Moreno Blanca, Mezzadra Riccardo, Chmielowski Bartosz, Ruchalski Kathleen, Shintaku I Peter, Sanchez Phillip J, Puig-Saus Cristina, Cherry Grace, Seja Elizabeth, Kong Xiangju, Pang Jia, Berent-Maoz Beata, Comin-Anduix Begoña, Graeber Thomas G, Tumeh Paul C, Schumacher Ton N M, Lo Roger S, Ribas Antoni Mutations Associated with Acquired Resistance to PD-1 Blockade in
Melanoma.
The New England journal of medicine.
2016; 375(9):
819-29.
Hugo Willy, Zaretsky Jesse M, Sun Lu, Song Chunying, Moreno Blanca Homet, Hu-Lieskovan Siwen, Berent-Maoz Beata, Pang Jia, Chmielowski Bartosz, Cherry Grace, Seja Elizabeth, Lomeli Shirley, Kong Xiangju, Kelley Mark C, Sosman Jeffrey A, Johnson Douglas B, Ribas Antoni, Lo Roger S Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy
in Metastatic Melanoma.
Cell.
2016; 165(1):
35-44.
Hugo Willy, Shi Hubing, Sun Lu, Piva Marco, Song Chunying, Kong Xiangju, Moriceau Gatien, Hong Aayoung, Dahlman Kimberly B, Johnson Douglas B, Sosman Jeffrey A, Ribas Antoni, Lo Roger S Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi
Resistance.
Cell.
2015; 162(6):
1271-85.
Moriceau Gatien, Hugo Willy, Hong Aayoung, Shi Hubing, Kong Xiangju, Yu Clarissa C, Koya Richard C, Samatar Ahmed A, Khanlou Negar, Braun Jonathan, Ruchalski Kathleen, Seifert Heike, Larkin James, Dahlman Kimberly B, Johnson Douglas B, Algazi Alain, Sosman Jeffrey A, Ribas Antoni, Lo Roger S Tunable-combinatorial mechanisms of acquired resistance limit the
efficacy of BRAF/MEK cotargeting but result in melanoma drug
addiction.
Cancer cell.
2015; 27(2):
240-56.
Shi Hubing, Hugo Willy, Kong Xiangju, Hong Aayoung, Koya Richard C, Moriceau Gatien, Chodon Thinle, Guo Rongqing, Johnson Douglas B, Dahlman Kimberly B, Kelley Mark C, Kefford Richard F, Chmielowski Bartosz, Glaspy John A, Sosman Jeffrey A, van Baren Nicolas, Long Georgina V, Ribas Antoni, Lo Roger S Acquired resistance and clonal evolution in melanoma during BRAF
inhibitor therapy.
Cancer discovery.
2014; 4(1):
80-93.
Lo Roger S Melanoma prognostics and personalized therapeutics at a crossroad.
The Journal of investigative dermatology.
2013; 133(2):
292-5.
Viros Amaya, Hayward Robert, Martin Matthew, Yashar Sharona, Yu Clarissa C, Sanchez-Laorden Berta, Zambon Alfonso, Niculescu-Duvaz Dan, Springer Caroline, Lo Roger S, Marais Richard Topical 5-Fluorouracil Elicits Regressions of BRAF Inhibitor-Induced
Cutaneous Squamous Cell Carcinoma.
The Journal of investigative dermatology.
2013; 133(1):
274-6.
Wilmott James S, Tembe Varsha, Howle Julie R, Sharma Raghwa, Thompson John F, Rizos Helen, Lo Roger S, Kefford Richard F, Scolyer Richard A, Long Georgina V Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF
inhibitor-resistant melanoma: a case illustrating the challenges for
personalized medicine.
Molecular cancer therapeutics.
2012; 11(12):
2704-8.
Krauthammer Michael, Kong Yong, Ha Byung Hak, Evans Perry, Bacchiocchi Antonella, McCusker James P, Cheng Elaine, Davis Matthew J, Goh Gerald, Choi Murim, Ariyan Stephan, Narayan Deepak, Dutton-Regester Ken, Capatana Ana, Holman Edna C, Bosenberg Marcus, Sznol Mario, Kluger Harriet M, Brash Douglas E, Stern David F, Materin Miguel A, Lo Roger S, Mane Shrikant, Ma Shuangge, Kidd Kenneth K, Hayward Nicholas K, Lifton Richard P, Schlessinger Joseph, Boggon Titus J, Halaban Ruth Exome sequencing identifies recurrent somatic RAC1 mutations in
melanoma.
Nature genetics.
2012; 44(9):
1006-14.
Graham Nicholas A, Tahmasian Martik, Kohli Bitika, Komisopoulou Evangelia, Zhu Maggie, Vivanco Igor, Teitell Michael A, Wu Hong, Ribas Antoni, Lo Roger S, Mellinghoff Ingo K, Mischel Paul S, Graeber Thomas G Glucose deprivation activates a metabolic and signaling amplification
loop leading to cell death.
Molecular systems biology.
2012; 8(7408):
589.
Gembarska Agnieszka, Luciani Flavie, Fedele Clare, Russell Elisabeth A, Dewaele Michael, Villar Stéphanie, Zwolinska Aleksandra, Haupt Sue, de Lange Job, Yip Dana, Goydos James, Haigh Jody J, Haupt Ygal, Larue Lionel, Jochemsen Aart, Shi Hubing, Moriceau Gatien, Lo Roger S, Ghanem Ghanem, Shackleton Mark, Bernal Federico, Marine Jean-Christophe MDM4 is a key therapeutic target in cutaneous melanoma.
Nature medicine.
2012; 487(7408):
.
Straussman Ravid, Morikawa Teppei, Shee Kevin, Barzily-Rokni Michal, Qian Zhi Rong, Du Jinyan, Davis Ashli, Mongare Margaret M, Gould Joshua, Frederick Dennie T, Cooper Zachary A, Chapman Paul B, Solit David B, Ribas Antoni, Lo Roger S, Flaherty Keith T, Ogino Shuji, Wargo Jennifer A, Golub Todd R Tumour micro-environment elicits innate resistance to RAF inhibitors
through HGF secretion.
Nature.
2012; 487(7408):
500-4.
Lo Roger S Receptor tyrosine kinases in cancer escape from BRAF inhibitors.
Cell research.
2012; 22(6):
945-7.
Shi Hubing, Moriceau Gatien, Kong Xiangju, Lee Mi-Kyung, Lee Hane, Koya Richard C, Ng Charles, Chodon Thinle, Scolyer Richard A, Dahlman Kimberly B, Sosman Jeffrey A, Kefford Richard F, Long Georgina V, Nelson Stanley F, Ribas Antoni, Lo Roger S Melanoma whole-exome sequencing identifies (V600E)B-RAF
amplification-mediated acquired B-RAF inhibitor resistance.
Nature communications.
2012; 3(9):
724.
Shi Hubing, Moriceau Gatien, Kong Xiangju, Koya Richard C, Nazarian Ramin, Pupo Gulietta M, Bacchiocchi Antonella, Dahlman Kimberly B, Chmielowski Bartosz, Sosman Jeffrey A, Halaban Ruth, Kefford Richard F, Long Georgina V, Ribas Antoni, Lo Roger S Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not
confer resistance to BRAF inhibitors.
Cancer discovery.
2012; 2(5):
414-24.
Paraiso Kim H T, Haarberg H Eirik, Wood Elizabeth, Rebecca Vito W, Chen Y Ann, Xiang Yun, Ribas Antoni, Lo Roger S, Weber Jeffrey S, Sondak Vernon K, John Jobin K, Sarnaik Amod A, Koomen John M, Smalley Keiran S M The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated
through diverse mechanisms.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2012; 18(9):
2502-14.
Lo Roger S Combinatorial therapies to overcome B-RAF inhibitor resistance in
melanomas.
Pharmacogenomics.
2012; 13(2):
125-8.
Su Fei, Viros Amaya, Milagre Carla, Trunzer Kerstin, Bollag Gideon, Spleiss Olivia, Reis-Filho Jorge S, Kong Xiangju, Koya Richard C, Flaherty Keith T, Chapman Paul B, Kim Min Jung, Hayward Robert, Martin Matthew, Yang Hong, Wang Qiongqing, Hilton Holly, Hang Julie S, Noe Johannes, Lambros Maryou, Geyer Felipe, Dhomen Nathalie, Niculescu-Duvaz Ion, Zambon Alfonso, Niculescu-Duvaz Dan, Preece Natasha, Robert Lídia, Otte Nicholas J, Mok Stephen, Kee Damien, Ma Yan, Zhang Chao, Habets Gaston, Burton Elizabeth A, Wong Bernice, Nguyen Hoa, Kockx Mark, Andries Luc, Lestini Brian, Nolop Keith B, Lee Richard J, Joe Andrew K, Troy James L, Gonzalez Rene, Hutson Thomas E, Puzanov Igor, Chmielowski Bartosz, Springer Caroline J, McArthur Grant A, Sosman Jeffrey A, Lo Roger S, Ribas Antoni, Marais Richard RAS mutations in cutaneous squamous-cell carcinomas in patients
treated with BRAF inhibitors.
The New England journal of medicine.
2012; 366(3):
207-15.
Poulikakos Poulikos I, Persaud Yogindra, Janakiraman Manickam, Kong Xiangju, Ng Charles, Moriceau Gatien, Shi Hubing, Atefi Mohammad, Titz Bjoern, Gabay May Tal, Salton Maayan, Dahlman Kimberly B, Tadi Madhavi, Wargo Jennifer A, Flaherty Keith T, Kelley Mark C, Misteli Tom, Chapman Paul B, Sosman Jeffrey A, Graeber Thomas G, Ribas Antoni, Lo Roger S, Rosen Neal, Solit David B RAF inhibitor resistance is mediated by dimerization of aberrantly
spliced BRAF(V600E).
Nature.
2011; 480(7377):
387-90.
Niehr Franziska, von Euw Erika, Attar Narsis, Guo Deliang, Matsunaga Doug, Sazegar Hooman, Ng Charles, Glaspy John A, Recio Juan A, Lo Roger S, Mischel Paul S, Comin-Anduix Begonya, Ribas Antoni Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in
melanoma cell lines with distinct driver mutations.
Journal of translational medicine.
2011; 9(15):
76.
Shi Hubing, Kong Xiangju, Ribas Antoni, Lo Roger S Combinatorial treatments that overcome PDGFR?-driven resistance of
melanoma cells to V600EB-RAF inhibition.
Cancer research.
2011; 71(15):
5067-74.
Atefi Mohammad, von Euw Erika, Attar Narsis, Ng Charles, Chu Connie, Guo Deliang, Nazarian Ramin, Chmielowski Bartosz, Glaspy John A, Comin-Anduix Begonya, Mischel Paul S, Lo Roger S, Ribas Antoni Reversing melanoma cross-resistance to BRAF and MEK inhibitors by
co-targeting the AKT/mTOR pathway.
PloS one.
2011; 6(12):
e28973.
Søndergaard Jonas N, Nazarian Ramin, Wang Qi, Guo Deliang, Hsueh Teli, Mok Stephen, Sazegar Hooman, MacConaill Laura E, Barretina Jordi G, Kehoe Sarah M, Attar Narsis, von Euw Erika, Zuckerman Jonathan E, Chmielowski Bartosz, Comin-Anduix Begoña, Koya Richard C, Mischel Paul S, Lo Roger S, Ribas Antoni Differential sensitivity of melanoma cell lines with BRAFV600E
mutation to the specific Raf inhibitor PLX4032.
Journal of translational medicine.
2010; 8(7326):
39.
Nazarian Ramin, Shi Hubing, Wang Qi, Kong Xiangju, Koya Richard C, Lee Hane, Chen Zugen, Lee Mi-Kyung, Attar Narsis, Sazegar Hooman, Chodon Thinle, Nelson Stanley F, McArthur Grant, Sosman Jeffrey A, Ribas Antoni, Lo Roger S Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or
N-RAS upregulation.
Nature.
2010; 468(7326):
973-7.
Lo Roger S, Witte Owen N Transforming growth factor-beta activation promotes genetic
context-dependent invasion of immortalized melanocytes.
Cancer research.
2008; 68(11):
4248-57.
|